The effect of exercise training on chronic heart failure patients

Effect of concurrent aerobic- resistance training on aerobic power, heart structure and function, heart rate variables, galectin-3 and N-terminal pro-brain natriuretic peptide in patients with chronic heart failure

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150531022498N24

Enrollment

Registered

2018-07-25

Start date

2018-06-05

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Heart Failure. Congestive heart failure, Congestive heart disease Right ventricular failure (secondary to left heart failure)

Interventions

Intervention 1: Intervention group: Aerobic training and concurrent resistance for eight weeks and three days a week, 60 minutes a day that progressive aerobic exercise with 60 to 90 percent of maximu

Eligibility

Sex/Gender

All

Age

52 Years to 78 Years

Inclusion criteria

Inclusion criteria: Patients with chronic heart failure in NYHA II-III Classification with ejection fraction(EF) > 20%

Exclusion criteria

Exclusion criteria: Patients with NYHA IV class Patients with acute myocarditis Patients with disorder exercise (such as severe aortic stenosis, severe hypertrophic cardiomyopathy (HOCM), etc.) Patients are not able to perform 6MWT ''. For example, osteoarthritis, knee surgery, cerebrovascular infarct , and so on Patients with specific cognitive impairment Patients with psychiatric and nervous disorders who are being treated with sedative medicines Patients with orthopedic, verbal and auditory problems

Design outcomes

Primary

Measure	Time frame
N-terminal pro-brain natriuretic peptide. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Serum level by ELISA method(n mol/ ml).;Aerobic Power. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Maximum heart rate, 6-Minute Walk Test(6MWT).;Structure and function of heart. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Echocardiography.;Heart rate variables. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Maximum heart rate.;Galectin-3. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Serum level by ELISA method(n mol/ ml).	—

Measure

Time frame

N-terminal pro-brain natriuretic peptide. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Serum level by ELISA method(n mol/ ml).;Aerobic Power. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Maximum heart rate, 6-Minute Walk Test(6MWT).;Structure and function of heart. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Echocardiography.;Heart rate variables. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Maximum heart rate.;Galectin-3. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Serum level by ELISA method(n mol/ ml).

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactzahra mahmoodi

Islamic Azad University

fmahmoodi1390@Gmail.com+98 13 3336 4861

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026